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(difference: 1±1%). The planned mean bladder dose (18.4 Gy) 
was slightly reduced in the repeat CTs (-6±7%). 
 
 
 
Conclusion: For the membranous urethra, rectum, and anus, 
the dose in the repeat CTs was higher than was planned. This 
warrants future research investigating whether increased 
dose leads to increased incidence of side effects and whether 
dose increases should be mitigated by treatment adaptations. 
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Purpose or Objective: Endpoints for this ethically approved 
clinical study:  
- Assess the feasibility of planning SABR for low-intermediate 
risk prostate cancer using flattening filter free volumetric arc 
therapy.  
- Assess safety of treatment delivery by recording RTOG 
scoring criteria of acute gastro-intestinal (GI) and genito-
urinary (GU) toxicity. 
 
Material and Methods: 25 patients were included, each has 
18 week toxicity data.  
Inclusion criteria: 
Written informed consent, 18 - 80 years, T1-T2 stage, WHO 
performance status ≤ 2. Initial PSA ≤ 20 ng/ml. Gleason score 
≤7 with histologically-proven prostate adenocarcinoma. No 
pathologic lymph nodes on CT/ MRI scans and no distant 
metastases. No previous prostate surgery, including 
transurethral resection of the prostate no TURP in past 6 
months. No previous active malignancy within the last 10 
years.  
A prescription dose of 35Gy in 5 fractions was treated 
alternate days. This was planned using Rapidarc VMAT 
planning on Varian Eclipse (V.10), treated using a Varian 
Truebeam STX.  
A clinically acceptable plan was determined by assessing the 
planned dose to GTV/PTV criteria and achieving dose 
constraints (table 1).  
 
GI, GU and skin toxicity was scored using Radiation therapy 
oncology group (RTOG) criteria. Baseline data was recorded 
before treatment commenced (baseline), week 4 and week 
18. 
 
Results: Results include first 25 patients.  
Age range was 52-78, median 70, initial PSA median 4.3-29.2, 
median 10.8ng/ml. All patients were successfully planned 
and treated with VMAT-FFF with plans being deemed 
clinically acceptable for 100% of patients.  
GU and GI toxicity at baseline, week 4 and week 18 is 
detailed for each grade below, respectively.  
GU toxicity: 
Grade 0 - 44%, 12%, 48%  
Grade 1 - 52%, 56%, 48%  
Grade 2 – 4%, 28%, 4%  
Grade 3 – 0%, 4%, 0%  
For GU toxicity, a statistically significant increase in toxicity 
was observed from baseline to week 4 (p=<0.01) and a 
significant reduction from week 4 to week 18 (p=<0.01). No 
significant difference was observed between baseline and 
week 18, with toxicity reducing to similar levels as baseline.  
GI toxicity (baseline, week 4, week 18): 
Grade 0 – 96%, 52%, 72%  
Grade 1 – 4%, 40%, 28%  
Grade 2 – 0%, 8%, 0%  
Grade 3 – 0%,0%, 0%  
GI toxicity significantly increased from baseline to week 4 
(p=<0.01). From week 4 to week 18, toxicity had reduced 
(p=<0.05). A significant difference was observed between 
baseline and week 18 (p=<0.05) with toxicity having reduced, 
but not having returned to baseline grade. 
 
Conclusion: Highly conformal plans were created for all 
patients. Toxicity was acceptable throughout, with toxicity 
at week 18 reducing to that of baseline for GU toxicity, and 
reducing significantly for GI toxicity. 1 patient experienced 
grade 3 GU toxicity at week 4, this resolved by week 10. 
Longer follow-up is required to assess late outcomes. 
 
OC-0557  
Feasibility of single fraction HDR brachytherapy in patients 
with prostate cancer: a planning study 
M. Roos
1Erasmus MC Cancer Center, Radiation Oncology, Rotterdam, 
The Netherlands 
1, C. De Pan1, I.K.K. Kolkman-Deurloo1, S. Aluwini1 
 
Purpose or Objective: To investigate the feasibility of single 
fraction High Dose Rate (HDR) brachytherapy (BT) as 
monotherapy for low risk prostate cancer. 
 
Material and Methods: CT scans of 30 patients were selected 
from our prostate HDR database. Patients were divided in 
groups based on prostate volume (< 40cc, 40-70cc and >70cc) 
and the number of needles used (13-16 and 17-22). The 
